Abeona Therapeutics (ABEO) Stock Price, News & Analysis

Company Overview

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Key Stats

• Today's Range: $5.82 to $5.91
• 50-Day Range: $5.09 to $6.02
• 52-Week Range: $3.05 to $9.01
• Volume: 63,106 shs
• Average Volume: 281,325 shs
• Market Capitalization: $253.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Buy

Abeona Therapeutics Stock Analysis - MarketRank™

Abeona Therapeutics scored higher than 85% of companies evaluated by MarketBeat, and ranked 158th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Abeona Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Abeona Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Abeona Therapeutics are expected to decrease in the coming year, from ($1.16) to ($1.23) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Abeona Therapeutics is -2.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Abeona Therapeutics is -2.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Abeona Therapeutics has a P/B Ratio of 9.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.46% of the float of Abeona Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Abeona Therapeutics has a short interest ratio ("days to cover") of 9.1.

Change versus previous month

Short interest in Abeona Therapeutics has recently decreased by 6.77%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Abeona Therapeutics does not currently pay a dividend.

Dividend Growth

Abeona Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -1.03

Percentage of Shares Shorted

6.46% of the float of Abeona Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Abeona Therapeutics has a short interest ratio ("days to cover") of 9.1.

Change versus previous month

Short interest in Abeona Therapeutics has recently decreased by 6.77%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.69

News Sentiment

Abeona Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Abeona Therapeutics this week, compared to 2 articles on an average week.

MarketBeat Follows

3 people have added Abeona Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Abeona Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,920.00 in company stock.

Percentage Held by Insiders

Only 5.40% of the stock of Abeona Therapeutics is held by insiders.

Percentage Held by Institutions

80.56% of the stock of Abeona Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ABEO Stock Analysis - Frequently Asked Questions

How have ABEO shares performed this year?

Abeona Therapeutics' stock was trading at $5.57 on January 1st, 2025. Since then, ABEO shares have increased by 5.3% and is now trading at $5.8650.
View the best growth stocks for 2025 here.

How were Abeona Therapeutics' earnings last quarter?

Abeona Therapeutics Inc (NASDAQ:ABEO) announced its quarterly earnings results on Monday, November, 15th. The biopharmaceutical company reported ($4.00) earnings per share for the quarter, hitting the consensus estimate of ($4.00).

When did Abeona Therapeutics' stock split?

Abeona Therapeutics shares reverse split on Tuesday, July 5th 2022. The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Who are Abeona Therapeutics' major shareholders?

Abeona Therapeutics' top institutional shareholders include Adage Capital Partners GP L.L.C. (8.98%), Millennium Management LLC (4.87%), Western Standard LLC (4.80%) and Rosalind Advisors Inc. (4.15%). Insiders that own company stock include Vishwas Seshadri, Brendan M O'malley, Michael Amoroso, Christine Berni Silverstein, Faith L Charles and Mark Alvino.
View institutional ownership trends.

How do I buy shares of Abeona Therapeutics?

Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Abeona Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Abeona Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), CymaBay Therapeutics (CBAY) and General Electric (GE).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 2/21/2025
• Next Earnings (Estimated): 3/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ABEO
• Previous Symbol: OTCMKTS:ACCP
• CUSIP: N/A
• CIK: 318306
• Web: www.abeonatherapeutics.com
• Phone: 214-665-9495
• Fax: 214-905-5101
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $18.00
• High Stock Price Target: $21.00
• Low Stock Price Target: $15.00
• Potential Upside/Downside: +209.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-54,190,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -203.27%
• Return on Assets: -64.56%

Debt

• Debt-to-Equity Ratio: 0.31
• Current Ratio: 6.12
• Quick Ratio: 6.12

Sales & Book Value

• Annual Sales: $3.50 million
• Price / Sales: 72.31
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.60 per share
• Price / Book: 9.70

Miscellaneous

• Outstanding Shares: 43,470,000
• Free Float: 41,124,000
• Market Cap: $253.08 million
• Optionable: Optionable
• Beta: 1.43